CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-modality support for clients

• SK pharmteco previously invested $350 million in CBM in 2022

An announcement is less than two years after an initial $350 million capital investment in 2022 and comes on the heels of SK pharmteco’s acquisition of Yposkesi, a French viral vector CDMO, in March 2021. Once the new deal is finalized, SK pharmteco will have a controlling stake in CBM, and the operations of CBM will be integrated with Yposkesi to establish a global CGT business unit with unprecedented capabilities and capacity.

“With CGT manufacturing sites in both Europe and the U.S., SK pharmteco is closer to its goal of being a leading CDMO that produces both chemical APIs and biologic drugs,” said Joerg Ahlgrimm, CEO of SK pharmteco. “As we continue our journey from being a leader in small molecule development and manufacturing to being a leader in multiple modalities, including CGT, we will ensure our focus remains on our unwavering dedication to providing lifesaving therapies to patients around the world and bringing solutions to our clients.”

SK pharmteco will have end-to-end cell and gene therapy offerings in both the U.S. and Europe, providing comprehensive services and expertise, including process development, plasmid DNA production, viral vector manufacturing, cell therapy processing, and fully integrated testing and analytics.

Additionally, SK pharmteco will continue to invest in building one of the largest CGT CDMOs in terms of capacity and capabilities, with a focus on emerging technologies and new approaches to complement the existing platforms offered to its clients in both adherent and suspension processes.

“The Center for Breakthrough Medicines team is truly excited to join the SK pharmteco family, a global leader in the CDMO industry,” said Audrey Greenberg, co-founder and chief business officer of CBM. “Working together with Yposkesi, AMPAC Fine Chemical, and SK Biotek, we are very well positioned to work with our clients in saving millions of lives around the world.”

SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate, and has 13 offices and manufacturing facilities across the U.S., Europe, and Korea, all with a combined vision to provide life-changing and lifesaving therapies to more than 200 million patients by 2026.